title: [23 and Me: how to make (a lot of) money out of your customers].
abstract: The announcement of several deals between the DTC genetics firm 23 and Me and Genentech, Pfizer and other corporations reveals the real business model of the company: selling access to sets of characterized patients for targeted drug development. This may be a useful strategy, but it raises a number of questions concerning the privacy of the company's customers and also of adequate compensation when they become valuable currency.
authors.affiliation: UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS,Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Jordan
mesh_terms: D035843:Biomedical Research / Q000639:trends; D002140:California; D003132:Commerce; D030881:Disclosure / Q000941:ethics; D032984:Ethics, Research; D005820:Genetic Testing / Q000191:economics* / Q000941:ethics; D006801:Humans; D007258:Informed Consent / Q000331:legislation & jurisprudence; D007753:Laboratories / Q000191:economics* / Q000941:ethics